The aim of this study was to verify whether the distribution of a treatment diary by a pharmacist could influence the adherence to oral treatment with imatinib, nilotinib, and dasatinib in patients with chronic myeloid leukaemia.
Methods
The level of adherence was calculated using the received daily dose/prescribed daily dose ratio and compared between patients who used a diary and those who did not.
Results
Forty-four (35.8%) of 123 patients with chronic myeloid leukaemia completed the diary: 20 (45.4%) receiving imatinib, 17 (38.6%) receiving nilotinib, and seven (15.9%) receiving dasatinib. Treatment adherence with the diary calculated using received daily dose/prescribed daily dose method was 93.6% (imatinib 94.9%, nilotinib 91.1%, and dasatinib 95.8%). Adherence during the period without a diary was 86.5% (84.9, 87.4, and 90%). Adherence was significantly greater with than without a diary (p < 0.0001).
Conclusions
The findings of this study that, in the case of chronic diseases, direct pharmacist–patient contact is important in order to maintain high levels of adherence, and a treatment diary is a valid means of doing this. According to these data, it is necessary to support similar patient-oriented programmes in order to ensure high levels of adherence and optimize drug management.
GelladWFGrenardJLMarcumZA. A systematic review of barriers to medication adherence in the elderly: looking beyond cost and regimen complexity. Am J Geriatr Pharmacother2011; 9: 11–23.
3.
Alvarez PayeroMMartínez López de CastroNUcha SamartínMet al.Medication non-adherence as a cause of hospital admissions. Farm Hosp2014; 38: 328–333.
4.
SeaburySAGuptaCNPhilipsonTJet al.PhRMA medication adherence advisory council. Understanding and overcoming barriers to medication adherence: a review of research priorities. J Manag Care Spec Pharm2014; 20: 775–783.
5.
BrownMTBussellJDuttaSet al.Medication adherence: truth and consequences. Am J Med Sci2016; 351: 387–399.
6.
BrownMTBussellJK. Medication adherence: WHO cares?Mayo Clin Proc2011; 86: 304–314.
7.
BriesacherBAAndradeSEFouayziHet al.Comparison of drug adherence rates among patients with seven different medical conditions. Pharmacotherapy2008; 28: 437–443.
8.
RolnickSJPawloskiPAHedblomBDet al.Patient characteristics associated with medication adherence. Clin Med Res2013; 11: 54–65.
9.
ZhaoYZabriskiSBertramC. Associations between statin adherence level, health care costs, and utilization. J Manag Care Spec Pharm2014; 20: 703–713.
10.
YeawJBennerJSWaltJGet al.Comparing adherence and persistence across 6 chronic medication classes. J Manag Care Pharm2009; 15: 728–740.
11.
ZelkoEKlemenc-KetisZTusek-BuncK. Medication adherence in elderly with polypharmacy living at home: a systematic review of existing studies. Mater Sociomed2016; 28: 129–132.
12.
IugaAOMcGuireMJ. Adherence and health care costs. Risk Manag Healthc Policy2014; 7: 35–44.
13.
KardasPLewekPMatyjaszczykM. Determinants of patient adherence: a review of systematic reviews. Front Pharmacol2013; 4: 91–91.
14.
SorensenTDPestkaDLBrummelARet al.Seeing the forest through the trees: improving adherence alone will not optimize medication use. J Manag Care Spec Pharm2016; 22: 598–604.
15.
ShinglerSLBennettBMCramerJAet al.Treatment preference, adherence and outcomes in patients with cancer: literature review and development of a theoretical model. Curr Med Res Opin2014; 30: 2329–2341.
16.
ColemanCILimoneBSobierajDMet al.Dosing frequency and medication adherence in chronic disease. J Manag Care Pharm2012; 18: 527–539.
17.
Calvo-CidonchaEGonzález-BuenoJAlmeida-GonzálezCVet al.Influence of treatment complexity on adherence and incidence of blips in HIV/HCV coinfected patients. J Manag Care Spec Pharm2015; 21: 153–157.
18.
MendysPZulligLLBurkholderRet al.Medication adherence: process for implementation. Patient Prefer Adherence2014; 8: 1025–1034.
19.
McCueDALohrLKPickAM. Improving adherence to oral cancer therapy in clinical practice. Pharmacotherapy2014; 34: 481–494.
20.
ShulerKM. Approaches to improve adherence to pharmacotherapy in patients with schizophrenia. Patient Prefer Adherence2014; 8: 701–714.
21.
van BovenJFStuurman-BiezeAGHiddinkEGet al.Medication monitoring and optimization: a targeted pharmacist program for effective and cost-effective improvement of chronic therapy adherence. J Manag Care Spec Pharm2014; 20: 786–792.
22.
National Collaborating Centre for Primary Care. Medicines adherence: involving patients in decisions about prescribed medicines and supporting adherence, London: NICE, 2009.
23.
MarinDBazeosAMahonFXet al.Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol2010; 28: 2381–2388.
24.
IbrahimAREliassonLApperleyJFet al.Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy. Blood2011; 117: 3733–3736.
25.
García-QueirugaMMartínez-LópezLMMartín-HerranzMIet al.Study on adherence to treatment with imatinib in chronic myeloid leukaemia and its association with therapeutic response. Farm Hosp2016; 40: 141–149.
26.
SantoleriFLasalaRRanucciEet al.Medication adherence to tyrosine kinase inhibitors: 2-year analysis of medication adherence to imatinib treatment for chronic myeloid leukemia and correlation with the depth of molecular response. Acta Haematol2016; 136: 45–51.
27.
UrquhartJ. The electronic medication event monitor. Lessons for pharmacotherapy. Clin Pharmacokinet1997; 32: 345–356.
28.
McHorneyCA. The Adherence Estimator: a brief, proximal screener for patient propensity to adhere to prescription medications for chronic disease. Curr Med Res Opin2009; 25: 215–238.
29.
SvarstadBLChewningBASleathBLet al.The brief medication questionnaire: a tool for screening patient adherence and barriers to adherence. Patient Educ Couns1999; 37: 113–124.
30.
MoriskyDEGreenLWLevineDM. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care1986; 24: 67–74.
31.
GardnerEMSharmaSPengGet al.Differential adherence to combination antiretroviral therapy is associated with virological failure with resistance. AIDS2008; 22: 75–82.
32.
VianaMLaszczynskaOMendesSet al.Medication adherence to specific drug classes in chronic heart failure. J Manag Care Spec Pharm2014; 20: 1018–1026.
33.
SidorkiewiczSTranVTCousynCet al.Development and validation of an instrument to assess treatment adherence for each individual drug taken by a patient. BMJ Open2016; 6: e010510–e010510.
34.
McCormackHMHorneDJSheatherS. Clinical applications of visual analogue scales: a critical review. Psychol Med1988; 18: 1007–1019.
35.
AljumahKHassaliMA. Impact of pharmacist intervention on adherence and measurable patient outcomes among depressed patients: a randomised controlled study. BMC Psychiatry2015; 15: 219–219.
36.
GanguliAClewellJShillingtonAC. The impact of patient support programs on adherence, clinical, humanistic, and economic patient outcomes: a targeted systematic review. Patient Prefer Adherence2016; 10: 711–725.
37.
VarmingARHansenUMAndrésdóttirGet al.Empowerment, motivation, and medical adherence (EMMA): the feasibility of a program for patient-centered consultations to support medication adherence and blood glucose control in adults with type 2 diabetes. Patient Prefer Adherence2015; 9: 1243–1253.
38.
WhisenhuntA. Social work and medical care: electronic reminders to address adherence. J Evid Based Soc Work2014; 11: 248–255.
39.
McMullenCKSaffordMMBosworthHBet al.Patient-centered priorities for improving medication management and adherence. Patient Educ Couns2015; 98: 102–110.
40.
ChummunHBolandD. How patient beliefs affect adherence to prescribed medication regimens. Br J Nurs2013; 22: 270–276.
SantoleriFSoricePLasalaRet al.Patient adherence and persistence with Imatinib, Nilotinib, Dasatinib in clinical practice. PLoS One2013; 8: e56813–e56813.
43.
AmitaiILeaderARaananiP. Adherence to tyrosine kinase inhibitors in chronic myeloid leukemia: the challenge that lies ahead. Acta Haematol2016; 136: 43–44.
44.
ChesneyMAIckovicsJRChambersDBet al.Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: the AACTG adherence instruments. Patient Care Committee & Adherence Working Group of the Outcomes Committee of the Adult AIDS Clinical Trials Group (AACTG). AIDS Care2000; 12: 255–266.
45.
WagnerGJ. Predictors of antiretroviral adherence as measured by self-report, electronic monitoring, and medication diaries. AIDS Patient Care STDS2002; 16: 599e608–599e608.
46.
StoneAAShiffmanSSchwartzJEet al.Patient compliance with paper and electronic diaries. Control Clin Trials2003; 24: 182e199–182e199.
47.
KhairK. Compliance, concordance and adherence: what are we talking about?Haemophilia2014; 20: 601–603.
48.
GorenoiVSchönermarkMPHagenA. Interventions for enhancing medication compliance/adherence with benefits in treatment outcomes. GMS Health Technol Assess2008; 3: Doc14–Doc14.
